The U.S. Centers for Disease Control and Prevention is observing a lower rate of severe allergic reactions in people in the United States who have received Pfizer Inc. and BioNTech SE’s Covid-19 vaccine.

Severe allergic reactions to Moderna Inc.’s coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said, after more than 4 million people received their first dose.

Moderna Inc. received a report from California’s health department that several people at a center in San Diego were treated for possible allergic reactions to the company’s Covid-19 vaccine from a particular batch.

Top U.S. Food and Drug Administration regulators said most Americans with allergies should be safe to receive the Covid-19 vaccine developed by Pfizer Inc. and Germany’s Biotech SE.

The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 17-4 to recommend Pfizer and BioNTech’s Covid-19 vaccine for Emergency Use Authorization (EUA) for individuals ages 16 years and older.

UK regulators stated that they received two reports of potential allergic reactions linked to the Covid-19 vaccine from Pfizer and BioNTech, according to the Associated Press.

Sociétés des Produits Nestlé, a part of Nestlé Health Science, acquired the outstanding shares of California-based Aimmune for $2.6 billion in cash following years of increasing its financial position in the food allergy-focused company.

EpiPens and other autoinjectors filled with epinephrine to treat severe allergic reactions may still be potent enough to work many months past their labeled expiration date, according to a study that concludes patients might need expensive refills less often.

Pfizer Inc. received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at the company’s Meridian Medical Technologies site.

Privately held pharmaceutical company kaléo announced that the U.S. Food and Drug Administration approved its supplemental New Drug Application for AUVI-Q (epinephrine injection, USP) 0.1 mg.